Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash & Equivalents (2020 - 2025)

Cellebrite DI's Cash & Equivalents history spans 6 years, with the latest figure at $124.5 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 35.06% to $124.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124.5 million through Dec 2025, down 35.06% year-over-year, with the annual reading at $124.5 million for FY2025, 35.06% down from the prior year.
  • Cash & Equivalents came in at $124.5 million for Q4 2025, down from $281.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $281.4 million in Q3 2025 to a low of $87.6 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $129.8 million (2021), against an average of $136.6 million.
  • Year-over-year, Cash & Equivalents surged 116.23% in 2023 and then crashed 35.06% in 2025.
  • Cellebrite DI's Cash & Equivalents stood at $133.8 million in 2021, then tumbled by 34.52% to $87.6 million in 2022, then soared by 116.23% to $189.5 million in 2023, then grew by 1.13% to $191.7 million in 2024, then plummeted by 35.06% to $124.5 million in 2025.
  • Per Business Quant, the three most recent readings for CLBT's Cash & Equivalents are $124.5 million (Q4 2025), $281.4 million (Q3 2025), and $179.2 million (Q2 2025).